Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
BR0210293A - An aqueous pharmaceutical preparation of cilostazol for parenteral use - Google Patents
[go: Go Back, main page]

BR0210293A - An aqueous pharmaceutical preparation of cilostazol for parenteral use - Google Patents

An aqueous pharmaceutical preparation of cilostazol for parenteral use

Info

Publication number
BR0210293A
BR0210293A BR0210293-5A BR0210293A BR0210293A BR 0210293 A BR0210293 A BR 0210293A BR 0210293 A BR0210293 A BR 0210293A BR 0210293 A BR0210293 A BR 0210293A
Authority
BR
Brazil
Prior art keywords
cilostazol
pharmaceutical preparation
aqueous pharmaceutical
parenteral use
acceptable salt
Prior art date
Application number
BR0210293-5A
Other languages
Portuguese (pt)
Inventor
Fujio Inoue
Keiichi Kawakami
Shinya Nagayasu
Hideshi Okamoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR0210293A publication Critical patent/BR0210293A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"UMA PREPARAçãO FARMACêUTICA AQUOSA DE CILOSTAZOL PARA UTILIZAçãO PARENTERAL". A presente invenção se refere a uma preparação farmacêutica aquosa de cilostazol para utilização parenteral. Em concordância com a presente invenção, a adição de um composto de ciclodextrina para a preparação farmacêutica aquosa de cilostazol para utilização parenteral que compreende cilostazol ou um sal farmacologicamente aceitável do mesmo como um ingrediente ativo, pode aumentar a solubilidade em água de cilostazol ou um sal farmacologicamente aceitável do mesmo, dando uma preparação farmacêutica aquosa para utilização parenteral de cilostazol ou um sal farmacologicamente aceitável do mesmo, da qual a estabilidade com o tempo no estado líquido é aperfeiçoada."A WATERY PHARMACEUTICAL PREPARATION OF CYLOSTAZOL FOR PARENTAL USE". The present invention relates to an aqueous pharmaceutical preparation of cilostazol for parenteral use. In accordance with the present invention, the addition of a cyclodextrin compound for the parenteral cilostazol aqueous pharmaceutical preparation comprising cilostazol or a pharmacologically acceptable salt thereof as an active ingredient may increase the water solubility of cilostazol or a salt. pharmaceutically acceptable salt thereof, giving an aqueous pharmaceutical preparation for parenteral use of cilostazol or a pharmacologically acceptable salt thereof, from which stability over time in the liquid state is improved.

BR0210293-5A 2001-06-13 2002-06-07 An aqueous pharmaceutical preparation of cilostazol for parenteral use BR0210293A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001179239 2001-06-13
JP2002127065A JP2003063965A (en) 2001-06-13 2002-04-26 Aqueous cilostazol preparation for injection
PCT/JP2002/005705 WO2002102383A1 (en) 2001-06-13 2002-06-07 Aqueous cilostazol preparation for injection

Publications (1)

Publication Number Publication Date
BR0210293A true BR0210293A (en) 2004-07-13

Family

ID=26616861

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210293-5A BR0210293A (en) 2001-06-13 2002-06-07 An aqueous pharmaceutical preparation of cilostazol for parenteral use

Country Status (11)

Country Link
US (1) US20040209843A1 (en)
EP (1) EP1396266A1 (en)
JP (1) JP2003063965A (en)
KR (1) KR100720886B1 (en)
CN (1) CN1223347C (en)
AR (1) AR034370A1 (en)
AU (1) AU2002306329B2 (en)
BR (1) BR0210293A (en)
CA (1) CA2443466A1 (en)
MX (1) MXPA03011480A (en)
WO (1) WO2002102383A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82561C2 (en) * 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Controlled release sterile aripiprazole formulation for injections, method for preparing aripiprazole formulation, and method for treating schizophrenia
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
KR100667367B1 (en) * 2005-05-10 2007-01-10 충남대학교산학협력단 Cilostazol composite composition with improved solubility and preparation method thereof
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
SI2170279T1 (en) 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Procedures for producing suspensions of aripiprazole and sublimation-dried formulations
AR067746A1 (en) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd A MEDICINAL PRODUCT TO TREAT GLAUCOMA THAT IT INCLUDES AS A COMPOSITE ACTIVE ITEM OF CYCLODEXTRINE - CILOSTAZOL CLATRATE
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US20110092456A1 (en) * 2009-10-19 2011-04-21 Yochai Birnbaum Methods of increasing cAMP levels and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B2 (en) * 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
SG11201407337QA (en) 2012-05-08 2014-12-30 Onyx Therapeutics Inc Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
KR101648740B1 (en) * 2014-09-04 2016-08-17 경상대학교산학협력단 Pharmaceutical composition for preventing heart failure or dilated cardiomyopathy by doxorubicin comprising cilostazol as effective component
JOP20200195A1 (en) 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids and formulations, and their uses
SMT202000202T1 (en) * 2015-11-06 2020-05-08 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
KR20240157128A (en) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. Neuroactive steroids, compositions, and uses thereof
CA3157999A1 (en) * 2019-11-22 2021-05-27 Pradeep SHIVAKUMAR Injectable compositions of ursodeoxycholic acid
JP7606530B2 (en) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド Treating chemosensory dysfunction caused by coronavirus infection
KR20230126654A (en) * 2022-02-23 2023-08-30 주식회사 엘지화학 Injectable formulation comprising isooxazoline derivatives and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
IT1263831B (en) * 1993-01-29 1996-09-04 Paolo Chiesi MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSTITUTED BY A BASIC-TYPE DRUG, AN ACID AND A CYCLODEXTRINE
EP1084149A1 (en) * 1998-05-29 2001-03-21 Janssen Pharmaceutica N.V. Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments
KR100708360B1 (en) * 1999-01-21 2007-04-17 브리스톨-마이어스스퀴브컴파니 Complexes and methods of las-farnesyltransferase inhibitors with sulfobutylether-7-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Also Published As

Publication number Publication date
WO2002102383A1 (en) 2002-12-27
EP1396266A1 (en) 2004-03-10
HK1064056A1 (en) 2005-01-21
CN1505513A (en) 2004-06-16
JP2003063965A (en) 2003-03-05
KR100720886B1 (en) 2007-05-22
MXPA03011480A (en) 2004-03-18
AU2002306329B2 (en) 2006-11-30
CA2443466A1 (en) 2002-12-27
US20040209843A1 (en) 2004-10-21
AR034370A1 (en) 2004-02-18
KR20040005995A (en) 2004-01-16
CN1223347C (en) 2005-10-19

Similar Documents

Publication Publication Date Title
BR0210293A (en) An aqueous pharmaceutical preparation of cilostazol for parenteral use
ES2244831T5 (en) Use of panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate for the production of a pharmaceutical composition for ophthalmological application
BR0317600A (en) heteroarylalkanoic acids as derivatives of integrin receptor antagonists
EA200900152A1 (en) PYRROLOTRIAZINKINASE INHIBITORS
WO2004067550A3 (en) Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
BR0109703A (en) Piperazine Derivatives
FR2805817B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
ES2196527T3 (en) DERIVATIVES OF 11,15-O-DIALQUILPROSTAGLANDINA E, ITS PRODUCTION PROCEDURE AND MEDICATIONS THAT INCLUDE THESE AS THE ACTIVE PRINCIPLE.
IS8502A (en) Azate cyclic heterocycles as cannabinoid receptor antagonists
CO5580767A2 (en) INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE
WO2008026048A3 (en) Stable injectable pharmaceutical compositions of docetaxel
EP1314719A4 (en) BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT
BRPI0413186A (en) fexofenadine composition and process for preparing it
BRPI0518231A2 (en) 2-starch-4-phenylthiazole derivatives, their preparation and their therapeutic application
NO20032261L (en) Medical preparations
BR0113590A (en) 7-oxopyridopyrimidines
NO20025035D0 (en) Oxadiazole derivatives that have anticancer effects
EA200300406A1 (en) PHARMACEUTICAL COMPOSITION OF DRUNEDARON FOR PARENTERAL INTRODUCTION
BR0104358A (en) Taxane formulations having improved solubility
BR0309283A (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by lyophilization of the preparation
WO2002026732A1 (en) Benzodiazepine derivative
BR0108313A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen
NO20031410L (en) Use of distamycin derivatives for the manufacture of drugs
BRPI0409217A (en) antimicrobial derivatives and analogues of [3.1.0] bicycloexylphenyloxazolidinone
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A., E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.